ACCESS TO HEALTHCARE FOR THE MOST VULNERABLE
Our approach for access to healthcare for the most vulnerable

OUR OBJECTIVES AND PRIORITIES

1 OBJECTIVE

Improve access to healthcare: Prevention, treatment and care for the most vulnerable in our fields of expertise

- Serving the needs of patients including for non-communicable diseases
- Contributing actively to the control, elimination or eradication of some infectious diseases

3 PRIORITIES

1. Delivering innovative medicines and vaccines to address unmet medical needs

2. Developing new business/affordability models to improve access to healthcare sustainably

3. Strengthening primary healthcare systems (capacity building, professionals training, patient empowerment, for example)
INFECTIOUS DISEASES are a leading cause of death worldwide, especially in low-income countries, in particular in young children.

More than 1 death out of 8 in the world (1) is caused by lower respiratory tract infections, diarrheal diseases, HIV/AIDS, tuberculosis and malaria.

(1) http://needtoknow.nas.edu/id/threats/global-killers/ Last accessed: August 2019

WHAT SANOFI DOES

Sanofi’s vaccine division brings a long and widely-recognized heritage in the groundbreaking discovery and development of vaccines that have saved millions of lives.

We also have a long legacy in non-vaccine infectious disease therapies such as antibiotics and antimalarials.
WHAT SANOFI DOES

A key partner in the Global Polio Eradication Initiative (GPEI)

More than 6 billion doses of oral polio vaccine (OPV) provided to UNICEF over the last two decades

Type 3 poliovirus (OPV3) vaccine strain donated to the WHO (World Health Organization) in 2011

130 million doses of inactivated polio vaccine (IPV) provided over 2014-17 at lowest worldwide price for 73 of the world's poorest countries.

CLOSE TO ERADICATION (1)

• A decrease of cases by over 99% since 1988
• From 350,000 cases of paralytic polio in 1988 to 33 in 2018
• Only 3 endemic countries

(1) http://polioeradication.org/polio-today/polio-now/ Last accessed: August 2019

Internal sources
WHAT SANOFI DOES

Since 1953, more than half a billion vaccine doses distributed to residents and travelers to endemic areas

A key partner in the EYE (Eliminate Yellow fever Epidemics) initiative with the support from WHO, GAVI – the Vaccine Alliance, UNICEF and more than 50 health partners

Major contributor to annual stockpile

27.5 million vaccine doses delivered to Africa in 2018, an all-time record for our yellow fever vaccine

Large investments in manufacturing capacities to scale up supply in coming years.

Internal sources

INCREASED RISK OF URBAN OUTBREAKS WITH CROSS-BORDER SPREAD

- Population movements, urbanization and resurgence of mosquitoes due to global warming
- No specific antiviral treatment. One injection provides lifelong protection
- Nearly one billion people in 27 high-risk African countries to be vaccinated by 2026 (1)

Last accessed: August 2019
Infectious diseases | Sleeping Sickness

WHAT SANOFI DOES

Partnership agreement with the WHO since 2001 donating $85 million from 2001 to 2018 ($5 million /year)

Signatory of the London Declaration (2) against Neglected Tropical Diseases

With Sanofi ’s contribution

- More than 40 million people screened
- Over 210,000 people treated and saved (1)

Co-development of an oral treatment with Drugs for Neglected Diseases initiative: positive scientific opinion by EMA (article 58) and approval by Democratic Republic of Congo Authorities

36 SUB-SAHARAN AFRICAN COUNTRIES AT RISK

- Fatal if not treated
- WHO targets:
  - elimination as a public health problem by 2020
  - interruption of transmission by 2030 (1)


(2) http://unitingtocombatntds.org/london-declaration Last accessed: August 2019

Internal sources
ONE CHILD STILL DIED FROM MALARIA EVERY 2 MINUTES IN 2017

- An estimated **219 million malaria cases** occurred worldwide, mainly in Africa (92%)
- There were more than **435,000 deaths from malaria**.
- **Children under 5 years accounted for 61% of all malaria deaths**, making this population the most vulnerable group affected by the disease.


WHAT SANOFI DOES

For decades, Sanofi has played a key role in fighting malaria in low and middle-income countries with a comprehensive range of drugs and efficient disease awareness programs.

Concretely, Sanofi:

- Contributes to provide an hemi-synthetic quality assured artemisinin combination therapy (ACT) with a sustainable pricing and safety stock for all patients with uncomplicated *Plasmodium falciparum* malaria infection
- Develops a primaquine formulation suitable for children
- Aims to provide the first prequalified artemether injectable for patients with severe malaria not having access to first line treatment
- Strengthens disease awareness efforts with innovative and efficient programs and tools targeting children

Internal sources
WHAT SANOFI DOES

Since the 1960’s, with the isolation of rifampicin, Sanofi has remained a key player in the field of tuberculosis pioneering innovative solutions to prevent and treat the disease. The new preventive 3HP regimen is an integral part of this continuous effort towards holistic approaches for ending TB.

As its vision is to fill public health gaps worldwide, Sanofi will drive appropriate initiatives towards the ultimate goal of ending tuberculosis in relevant countries:

- Launching a global awareness campaign,
- Providing new tools to improve educational efforts for healthcare professionals and the general public,
- Establishing bold partnerships and technical support for TB prevention and care to countries most in need,
- Developing innovative and cost-effective therapeutic solutions to answer unmet needs.

AMONG THE 10 LEADING CAUSES OF MORTALITY WORLDWIDE (1)

- The “number one” killer due to an infectious disease
- Every 18 seconds a person dies from tuberculosis (TB)
- In 2017, 10 million people fell ill with TB

(1) https://www.who.int/tb/publications/factsheet_global.pdf?ua=1/
Last accessed: August 2019

Infectious diseases | Tuberculosis
WHAT SANOFI DOES

Since 2006, Sanofi contributes to the WHO’s work on educating children in endemic countries, training healthcare workers, strengthening capacities of national programs, intensifying epidemiological surveillance, screening and case management.

Sanofi manufactures a treatment for leishmaniasis.

FROM 700,000 TO 1 MILLION NEW CASES OF LEISHMANIASIS

- 26,000 to 65,000 deaths are recorded every year worldwide
- High stigma, especially for cutaneous leishmaniasis

http://www.who.int/news-room/fact-sheets/detail/leishmaniasis/
Last accessed: August 2019
Non-communicable diseases

**NON-COMMUNICABLE DISEASES (NCDs)**

41M DEATHS ANNUALLY WORLDWIDE (1)

- Cancers
- Cardiovascular diseases
- Chronic respiratory diseases
- Diabetes
- Mental disorders

**WHAT SANOFI DOES**

Sanofi, together with 24 other pharma companies and 6 partners* launched the Access Accelerated Initiative (AAI) (2) — a new coalition to address the burden of NCDs in low and lower-middle income countries.

* The World Bank, the Union for International Cancer Control, the World Heart Federation, PATH, the NCD Alliance and BIO Venture for Global Health

(1) Leading causes of death worldwide
(2) https://accessaccelerated.org/ Last accessed: August 2019
THE NUMBER OF CHILDREN AND ADOLESCENTS WITH DIABETES IS INCREASING EVERY YEAR

- Every 4 minutes a child is diagnosed with diabetes (1)
- Type 2 diabetes in childhood has the potential to become a global public health issue leading to serious health outcomes (2)

https://www.idf.org/our-activities/education/kids-project.html
https://www.diabetesatlas.org/resources/2017-atlas.html/ Last accessed: August 2019
https://www.diabetesatlas.org/resources/2017-atlas.html/ Last accessed: August 2019

WHAT SANOFI DOES

Kids & Diabetes in Schools (KiDS)

In a school setting:
- Support children with type 1 diabetes
- Raise awareness on healthy lifestyle to prevent type 2 diabetes

Targets: teachers, school nurses and staff, children and parents

KiDS is launched in Brazil, Egypt, Hungary, India, Japan, Pakistan, Poland and the United Arab Emirates

PARTNERS
- International Diabetes Federation (IDF)
- International Society for Pediatric Adolescent Diabetes (ISPAD)
WHAT SANOFI DOES

“Diabetes with Dignity” in India

To pilot feasibility and effectiveness of a model for enhanced care of diabetes mellitus in adults in a rural community through community health workers (ASHA)

Targets: ASHA, primary care physicians, patients and communities

Project launched in Pune district, Maharashtra, India

PARTNERS

- Diabetes Chelladaram Institute
- Public health foundation of India

APPROX. 425 MILLION ADULTS (20-79 YEARS) ARE LIVING WITH DIABETES AND HALF OF THEM ARE UNDIAGNOSED

- Diabetes is responsible for 4 million deaths worldwide
- In many parts of the world, patients do not have access to specialist doctors. Therefore it is important to consider non-physician field workers for patient education, and motivation to improve compliance

Non-communicable diseases | Diabetes & Hypertension

WHAT SANOFI DOES

Diabetes and Hypertension clinics in sub-Saharan Africa

Support the management of diabetes and hypertension through the setting of Diabetes and Hypertension clinics. This includes training of healthcare professionals, providing material and education.

Targets: healthcare professionals, patient associations, patients

Project launched in Ivory Coast, Cameroon and Senegal

PARTNERS

- Ministries of Health
- UNFM (université Francophone Numérique Mondiale)

CARDIOVASCULAR DISEASES (CVD) ARE THE WORLD’S BIGGEST KILLERS WITH 17.9 MILLION DEATHS PER YEAR

- 1 out of 10 people aged 30-70 die from CVD
- More than 85% of CVD deaths occur in low & middle income countries

https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases/
Last accessed: August 2019
WHAT SANOFI DOES

Fight Against STigma (FAST) program

Improve access to mental health and epilepsy care in low and middle-income countries

Since 2008, launched in Armenia, Benin, Bolivia, Cambodia, Cameroon, Comoros, Guatemala, Laos, Madagascar, Mali, Mauritania, Morocco and Myanmar.

PARTNERS
- World Association of Social Psychiatry (WASP)
- Institute of Epidemiology & Tropical Neurology (IENT)

450 MILLION PEOPLE WORLDWIDE SUFFER FROM A MENTAL DISORDER (1)

- In low and middle-income countries, 80% of people with mental disorders are not treated
- Main barriers to access to care: inadequate training of primary healthcare professionals, traditional beliefs and stigmatizations of patients

(1) https://www.who.int/news-room/fact-sheets/detail/mental-disorders/
Last accessed: August 2019
WHAT SANOFI DOES

My Child Matters (1)

Improving access to early diagnosis and care

58 projects in 42 countries enabling treatment access for 85,000 children since 2006

Training for more than 25,000 healthcare professionals

PARTNERS

- International Society of Paediatric Oncology, International Union against Cancer / City Cancer Challenge,
- St Jude Children’s Research Hospital, Alliance Mondiale Contre le Cancer and GroupeFranco-Africain d’Oncologie Pédiatrique


(2) Howard SC et al. The MyChild Matters programme: effect of public-private partnerships on paediatric cancer care in low-income and middle-income countries. Lancet Oncol 2018;19:e252-e266